SCUELJapan healthcare data

Home › Therapeutic areas › Antibiotics acting mainly on Gram-negative bacteria

Japan market screening · Therapeutic class

Antibiotics acting mainly on Gram-negative bacteria in Japan

主としてグラム陰性菌に作用するもの · Japan Standard Commodity Classification

11 molecules in this class are marketed in Japan across 31 products. 0 of those products are not shipping normally today — 0.0% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.

11Molecules
31Marketed products
0Products constrained

Molecules in this class

Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.

MoleculeProducts CompaniesConstrained Supply mix
Amikacin Sulfateアミカシン硫酸塩116—
Tobramycinトブラマイシン53—
Polymixin B SulfateポリミキシンB硫酸塩41—
Aztreonamアズトレオナム21—
Colistin Sodium Methanesulfonateコリスチンメタンスルホン酸ナトリウム22—
Isepamicin Sulfateイセパマイシン硫酸塩21—
Cefiderocol Tosilate Sulfate Hydrateセフィデロコルトシル酸塩硫酸塩水和物11—
Kanamycin Monosulfateカナマイシン一硫酸塩11—
Relebactam Hydrate / Imipenem Hydrate / Cilastatin Sodiumレレバクタム水和物・イミペネム水和物・シラスタチンナトリウム11—
Spectinomycin Hydrochloride Hydrateスペクチノマイシン塩酸塩水和物11—
Tigecyclineチゲサイクリン11—
Normal supply Limited supply Supply suspended

How to read this

Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.

Screening this area in Japan?

Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.

Send an enquiry

Our Database Division replies in English within three business days (Japan time).